These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 12228846

  • 1. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension.
    Motwani JG.
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):72-8. PubMed ID: 12228846
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 5. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 6. Modulation of the renin-angiotensin-aldosterone system and cough.
    Lacourcière Y, Lefebvre J.
    Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
    [Abstract] [Full Text] [Related]

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 8. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension.
    Waeber B.
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):43-50. PubMed ID: 15030296
    [Abstract] [Full Text] [Related]

  • 10. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 11. RAS inhibition in hypertension.
    Ibrahim MM.
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [Abstract] [Full Text] [Related]

  • 12. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [Abstract] [Full Text] [Related]

  • 14. Managing hypertension using combination therapy.
    Frank J.
    Am Fam Physician; 2008 May 01; 77(9):1279-86. PubMed ID: 18540493
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 01; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 16. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR.
    J Hum Hypertens; 2007 Oct 01; 21(10):770-9. PubMed ID: 17597800
    [Abstract] [Full Text] [Related]

  • 17. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM.
    Acta Diabetol; 2005 Apr 01; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [Abstract] [Full Text] [Related]

  • 18. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Lyle PA, Tershakovec AM, Devereux RB, Oparil S, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Wedel H.
    Expert Opin Emerg Drugs; 2005 Nov 01; 10(4):729-45. PubMed ID: 16262560
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 01; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 20. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
    Burnier M.
    Drugs; 2002 Mar 01; 62 Spec No 1():21-9. PubMed ID: 12036386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.